Patents Examined by My-Chau T Tran
  • Patent number: 11479564
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: October 25, 2022
    Assignee: Valo Health, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Judith D. Kuntz, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • Patent number: 11478454
    Abstract: Disclosed herein are methods of treating a subject with a bacterial infection, or preventing a bacterial infection, comprising administering to the subject an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. Also described are methods of inhibiting bacterial growth in a plant comprising contacting the plant with an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. The methods are effective against an array of bacterial pathogens in various animals and plants.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: October 25, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: Gireesh Rajashekara, Loic Deblais, Yosra A. Helmy, Dipak Kathayat, Sally A. Miller
  • Patent number: 11478467
    Abstract: Compounds of Formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof; processes and intermediates for preparation thereof, compositions thereof, and uses thereof; are provided. Pharmaceutical compositions comprising a compound of Formula I, or enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof; wherein the compound is a double and/or triple agent or ligand for CYP2D6, 5-HT2A, and/or 5HT2C receptors, and/or acetylcholinesterase are provided.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: October 25, 2022
    Inventors: Sreenivasarao Vepachedu, Hans J Moebius, Anton Bespalov
  • Patent number: 11478445
    Abstract: The present invention relates to a method for the treatment of acute myeloid leukemia (AML) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of the presently-described formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC105P.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 25, 2022
    Assignee: Bionomics Ltd.
    Inventor: Tina Lavranos
  • Patent number: 11471431
    Abstract: The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: October 18, 2022
    Assignee: LANTERN PHARMA INC.
    Inventor: Frederick H. Hausheer
  • Patent number: 11464767
    Abstract: Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: October 11, 2022
    Assignee: CONCENTRIC ANALGESICS, INC.
    Inventors: John F. Donovan, Craig Husfeld
  • Patent number: 11458149
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: October 4, 2022
    Assignee: IKENA ONCOLOGY, INC.
    Inventor: Alfredo C. Castro
  • Patent number: 11458144
    Abstract: Methods for administering compounds provide a rapid treatment for sickle cell disease (SCD) to inhibit or reverse red blood cell sickling. The compounds are a group of 5-hydroxymethylfurfural (5-HMF) analogs modified to increase water-solubility. The compounds can be formulated in an aqueous carrier and administered intravenously for immediate uptake into red blood cells (RBCs) within hours, rather than days or weeks. In vitro experiments demonstrated rapid uptake into RBCs and increased O2 affinity of HbS to an equilibrium point within 30 to 90 minutes. The compounds have a desired level of safety as well as a short half-life, both of which are compatible with acute usage. Thus, the methods of treatment rapidly achieve therapeutic steady-state drug levels, making it possible to deliver a treatment in critical emergency care situations to prevent, reverse and otherwise treat acute sickling or anemia.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: October 4, 2022
    Assignees: KING ABDULAZIZ UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIA, VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Moustafa E. El-Araby, Abdelsatter M. Omar, Osheiza Abdulmalik, Martin K. Safo
  • Patent number: 11452727
    Abstract: The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. In some embodiments, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat lung cancer, e.g., non-small cell lung cancer.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: September 27, 2022
    Assignee: Epizyme, Inc.
    Inventors: Maria Alejandra Raimondi, Dorothy Brach
  • Patent number: 11439648
    Abstract: The present invention discloses methods of treatment, prevention and/or amelioration of radiation dermatitis caused by radiotherapy, by administration to a subject in need thereof of a topical composition comprising a therapeutically or prophylactically effective amount of at least one BRaf inhibitor of this invention, thus treating, preventing and/or ameliorating the effects of radiation dermatitis.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: September 13, 2022
    Assignee: Lutris Pharma Ltd.
    Inventors: Noa Shelach, Noa Lowenton-Spier
  • Patent number: 11439612
    Abstract: Eflornithine is an agent that can be used to treat glioma, especially glioma of WHO Grade II or Grade III such as anaplastic glioma. Eflornithine can suppress or prevent mutations in glioma which can cause the glioma to progress to a higher grade. The present invention describes pharmaceutical compositions that contain eflornithine or a derivative, analog, or prodrug thereof. The pharmaceutical compositions can be prepared in a number of dosage forms and may contain another therapeutically active agent or an agent that enhances the therapeutic activity of the elformithine or the derivative, analog, or prodrug thereof. The present invention also describes a kit that includes dosage forms of pharmaceutical compositions according to the present invention.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: September 13, 2022
    Assignee: ORBUS THERAPEUTICS, INC.
    Inventors: Victor A. Levin, Noymi Yam, Alexander Vakoula
  • Patent number: 11426408
    Abstract: The present invention relates to the use of serotonergic compounds for the treatment of virus-induced thrombocytopenia. More particularly, the invention relates to methods of treating thrombocytopenia by blocking serotonin activity. For example, inhibitors of receptor 5HT2A and/or receptor 5HT1A and/or inhibitors of mast cell degranulation and/or inhibitors of serotonin uptake may be used. Preferably, the thrombocytopenia is induced by dengue or Japanese Encephalitis virus, and the inhibitors are preferably ketanserin, WAY-100135, sarpogrelate, or fluoxetine.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 30, 2022
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Ashley Lauren St. John, Mohamad Fadhli Bin Masri, Abhay Rathore
  • Patent number: 11426419
    Abstract: Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 30, 2022
    Assignee: Duke University
    Inventor: Eric J. Benner
  • Patent number: 11424006
    Abstract: Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: August 23, 2022
    Assignee: Psomagen, Inc.
    Inventors: Zachary Apte, Jessica Richman, Daniel Almonacid, Valeria Marquez, Ingrid Araya, Melissa Alegria, Mario Saavedra, Luis Gomez, Janyra Espinoza, Javier Gimpel, Eduardo Morales, Rodrigo Ortiz
  • Patent number: 11413287
    Abstract: There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: August 16, 2022
    Assignee: ALTAVANT SCIENCES GmbH
    Inventors: Steve Wring, Magdalena Alonso-Galicia, Thomas Pack, Julie Rurka, David Carpenter, Melissa Rhodes
  • Patent number: 11413273
    Abstract: The present invention provides a preventive or therapeutic agent for pulmonary hypertension, including a compound represented by the following formula (I) or a salt thereof: where: —A— represents —NH—, —S—, or —O—; R1 and R2 are identical to or different from each other, and each represent a hydrogen atom or an alkyl group; R3 represents a hydrogen atom, a halogen atom, or an alkyl group; R4 represents a hydrogen atom or an alkyl group; R5 represents a hydrogen atom or an alkyl group; R6 and R7 are identical to or different each other, and each represent a hydrogen atom, a halogen atom, or an alkyl group; and R6 and R7 may form an unsaturated hydrocarbon six-membered ring together with a carbon atom to which R6 is bonded and a carbon atom to which R7 is bonded.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: August 16, 2022
    Assignee: TOHOKU UNIVERSITY
    Inventors: Hiroaki Shimokawa, Yoshiteru Oshima, Haruhisa Kikuchi, Jyunken Aoki, Takayuki Doi, Kuniyuki Kano, Kimio Satoh, Ryo Kurosawa
  • Patent number: 11406643
    Abstract: Provided herein are methods for the treatment of brain metastasis by administering a kinase inhibitor targeted to a metastasis-promoting kinase identified by an in vivo kinase screen.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: August 9, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Dihua Yu, Frank Lowery, Chenyu Zhang, Sunil Acharya, Ping Li
  • Patent number: 11400103
    Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one reactive dicarbonyl scavenger compound, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: August 2, 2022
    Assignee: Vanderbilt University
    Inventors: John A. Oates, Olivier Boutaud, Irene Zagol-Ikapitte
  • Patent number: 11395820
    Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: July 26, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Pearlie Burnette, Harshani Lawrence, Nicholas J. Lawrence
  • Patent number: 11382885
    Abstract: The disclosure provides compositions comprising amino acids, individually and in combination, and methods of making the compositions and methods of using the compositions as pharmaceutically active agents to, inter alia, treat disease in animals, including humans.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: July 12, 2022
    Assignee: The Regents of the University of California
    Inventors: Clarissa J. Nobile, Megha Gulati